Advertisement

Topics

Popular Biotech News, Healthcare News and Pharma News

17:08 EDT 4th May 2016 | BioPortfolio

Shire Outlines Baxalta Integration Strategy

Dublin-based specialty firm announces 14% sales growth for the first quarter, and outlines the "inverted pyramid" method it uses to integrate acquired companies, such as Dyax.

GE Healthcare Introduces ÄKTA avant 150 Liquid Chromatography System for Accelerated Scale-up

• For speed, scalability and security Uppsala, Sweden, 6 September 2010 – GE Healthcare, a unit of General Electric Company (NYSE: GE), announces the launch of ÄKTA™ avant 150, the second system in the new generation of ÄKTA liquid chromatography systems. ÄKTA avant 150 complements the ÄKTA avant 25 system to fully exploit the advantages of modern BioPro...

MonoSol Rx and Midatech Launch MidaSol Therapeutics LP

  Strategic Initiative Focused on Partnering/Licensing of Innovative Diabetes Therapies Combines Monosol Rx’ Proprietary PharmFilm® and Midatech’s Proprietary MidaForm™ Nanoparticle Technologies Warren, New Jersey and Oxford, UK, 5 January 2012 – MonoSol Rx LLC, the developer of PharmFilm® drug delivery technology, and Midatech Ltd., the developer of...

Biotin (Cerenday) for primary and secondary progressive multiple sclerosis ‒ first line

Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acid synthesis. Very high doses of biotin may be efficacious in multiple sclerosis (MS) by promoting myelin repair through activation of acetyl-CoA carboxylase, and by enhancing energy production in demyelinated neurons t...

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

Cancer-associated genetic alterations induce expression of tumour antigens that can activate CD8+ cytotoxic T cells (CTLs), but the microenvironment of established tumours promotes immune tolerance through poorly understood mechanisms. Recently developed therapeutics that overcome tolerogenic mechanisms activate tumour-directed CTLs and are effective in some human cancers. Immune mechanisms also a...

Biosimilar On Hold: Sandoz’s Zarxio Launch Delayed Indefinitely

Federal appeals court blocks filgrastim-sndz from reaching market pending resolution of Neupogen maker Amgen’s appeal over ‘patent dance.’

Co-danthramer and Strong Co-danthramer capsules discontinued

Napp has discontinued Co-danthramer (dantron/poloxamer 188 25mg/200 mg) and Strong Co-danthramer (dantron/ poloxamer 188 37.5mg/500 mg) capsules. Napp expects stocks of Co-danthramer capsules to last until the end of June 2015 and stocks of Strong Co-danthramer capsules to last until the end of December 2015. Alternative suspension formulations of Co-danthramer are ...

IMS Health to Acquire ViS Research

Clinical Informatics News Brief | IMS Health tweeted out news of its acquisition of ViS Research last week during the DIA annual meeting.         

Architecture of the mammalian mechanosensitive Piezo1 channel

Piezo1, a mechanosensitive cation channel, senses shear stress of blood flow for proper blood vessel development, regulates red blood cell function and controls cell migration and differentiation; here a trimeric architecture of this novel class of ion channel is reported, suggesting that Piezo1 may use its peripheral propeller-like ‘blades’ as force sensors to gate the central ion-conducting ...

Exclusive: Senior HCA ‘bridging’ role will be piloted next year

Plans for widespread changes to the way nurses and care assistants are trained are underway, with new standards for a senior healthcare assistant “bridging” role due to be piloted next year.

FDA approves Relypsa's Veltassa

FDA approved Veltassa patiromer (RLY5016) from Relypsa Inc. (NASDAQ:RLYP) to treat hyperkalemia. The approval comes with a black box warning that recommends against taking Veltassa within six hours of other oral medications. The high-capacity oral potassium binder binds to many orally administered drugs, potentially reducing their effects. Veltassa must be dispensed with a patient medication guide...

Silent Partner Launches SmartPatch to Silence Snoring

Silent Partner SmartPatch, the world's first noise canceling sleep product, is the latest in innovative audio technology that eliminates unwanted snoring sounds. Silent Partner is introducing a simple solution for snoring sufferers on Indiegogo San Francisco, CA (PRWEB) November 10, 2015 Silent Partner, the first noise cancellation SmartPatch for quieting snoring noise, today launched its cro...

KSQ Therapeutics

KSQ Therapeutics, Inc. is a functional genomics company. We have developed a novel genetics tool that allows us to screen the human genome to uncover information on specific diseases. We utilize this knowledge to target drugs for treatment of these diseases.

Fostair® (beclometasone and formoterol) 200/6 high strength formulation now available for asthma maintenance therapy at no additional cost

Manchester, 1 December 2015 – Chiesi Limited today announced that the high strength formulation of Fostair (beclometasone/formoterol) 200/6 is now available for the regular treatment of adult asthma where the use of an inhaled corticosteroid (ICS) and long-acting beta-2-agonist (LABA) combination product is appropriate and where treatment needs to be stepped up. The introduction of the new...

Pharmacology: On the mode of action of mirabegron

Mirabegron has been shown to cause relaxation of the isolated mouse urethra, partly through blockade of α1A-adrenoceptors and α1D-adrenoceptors. However, although this effect might be an interesting pharmacological in vitro observation, it seems to have no relevance for the clinical use of mirabegron in the treatment of the overactive bladder.

ASOthera Pharmaceuticals

ASOthera Pharmaceuticals is a privately-held biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases. ASOthera’s technology is based on research from the laboratory of Professor Adrian Krainer at Cold Spring Harbor Laboratory (CSHL), the inventor of Isis-SMNRx (in Phase 3 for Spinal Muscular Atrophy) and...

Holidays present hard road for recovering drug addicts

The holidays can be a tough time for addicts in their first year of recovery. Kylee Moriarty's family should know.

Which drugs are going off-patent in 2016?

This will be a year in which generic drugmakers will have plenty of fodder – more than two dozen major drugs are going off-patent in 2016.

Box: Acousia Therapeutics GmbH Corporate Profile

Regrowing hearing Acousia Therapeutics GmbH Tübingen, Germany Technology: Small molecules that induce dedifferentiation of supporting cells to progenitor cells, and then differentiation of progenitor cells into …

Bluefin BioMedicine

BAP Pharma Opens U.S. Headquarters in Landing, NJ

NewsBAP Pharma announced the opening of its new U.S. headquarters in Landing, New Jersey.Contributed Author: Choose New Jersey, Inc.Topics: Facility

Magellan Health to Expand Capabilities Related to Long-Term Services and Supports

Magellan Health, Inc. (NASDAQ: MGLN) today announced that it has entered into an agreement to acquire The Management Group, LLC, (TMG) a company with 30 years of expertise in community-based long-term services and supports. Magellan Health plans to leverage the capabilities gained through this acquisition as it seeks to expand its footprint in managed ...

Two GPs face charges of manslaughter over death of boy in 2012

Two GPs have appeared in court charged with the manslaughter by gross negligence of a 12 year old patient who died in December 2012 in Wales.Joanne Rudling, 45, and Lindsey Thomas, 42, entered not...

Lilly's lung cancer drug Portrazza wins EU approval as first-line biologic

Portrazza won approval in the U.S. in November 2015, but Lilly has faced some criticism over the drug's $11,430/month price tag.  

RPS/RCGP joint conference: The challenge of polypharmacy, from rhetoric to reality - 20 April 2016

The Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners (RCGP) are holding a joint conference on 20 April 2016 to explore how closer working between the professions can improve care for patients with multiple long term conditions.

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016

LONDON, March 9, 2016 /PRNewswire/ -- SummaryDelveInsight's PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016 gives an insight on the PD-1 and PD-L1 inhibitors, which are amongst the highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 45 drugs in pipeline with approximate 245 active clinical ...

Gum Disease Connected to Open-Angle Glaucoma

Recent tooth loss and periodontal disease appears to be associated with the risk for primary open-angle glaucoma, especially cases with early paracentral visual field loss, new research shows. Medscape Medical News

Study Shows How Stem Cells Might Restore Bones Damaged by Osteoporosis

A study recently published in STEM CELLS Translational Medicine points the way to a new, potentially restorative treatment for age-related or type II osteoporosis. Durham, NC (PRWEB) March 22, 2016 A study recently published in STEM CELLS Translational Medicine points the way to a new, potentially restorative treatment for age-related or type II osteoporosis. When a single dose of a certain type ...

Vivex Biomedical, Inc. and Arthrex, Inc. Enter into Long Term Agreement

MARIETTA, Ga., March 31, 2016 /PRNewswire/ -- Vivex Biomedical, Inc. and Arthrex Inc. have signed a new long-term agreement that strengthens the partnership between a leading provider of proprietary biologics and a premier innovator of orthopedic surgical solutions. The multi-year commitment reinforces the vision shared by Vivex Biomedical and Arthrex to progress clinical, surgical and the...

X-ray structures and mechanism of the human serotonin transporter

X-ray crystal structures of the human serotonin transporter (SERT) bound to the antidepressants (S)-citalopram or paroxetine show that the antidepressants lock the protein in an outward-open conformation, and directly block serotonin from entering its binding site; the structures define the mechanism of antidepressant action in SERT and pave the way for future drug design.

Report: Sam's Club's Jill Turner-Mitchael keynotes Northwest Arkansas Council’s Health Care Summit

Jill Turner-Mitchael, SVP overseeing health and wellness for Sam’s Club, was the keynote speaker at the Northwest Arkansas Council’s Health Care Summit in Rogers on Wednesday, April 6, Talk Business and Politics reported Thursday. Turner-Mitchael addressed a number of ways Sam's Club is materially lowering healthcare costs - for example, Sam’s Club business members ...

What happened this week? Top 15, BIO-Europe Spring, Sci-Hub

1. Get to know 15 Awesome Biotechs in Paris 2. How can we Optimise DNA Extraction from Human Blood for more Sensitive NGS Analysis? 3. Interviewing one of the Leading Biotech Investors in Scandinavia 4. This 27-year-old Woman is Shaking ... This awesome article What happened this week? Top 15, BIO-Europe Spring, Sci-Hub appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Former Scottish chief medical officer resigns from BMA over ȷunior doctors’ action

The former chief medical officer for Scotland, Mac Armstrong, has resigned from the BMA after more than 40 years because of the decision by junior doctors in England to hold an all-out strike over...

Forbion Closes Third Fund, 'Agnostic' On When To Invest

Forbion Capital Partners has conducted the final closing of its third main fund Forbion Capital Fund III (FCF III), raising a total of €183m. Despite the Netherlands-based venture firm closing its last fund - FCF II - in 2010 when the investment...

InSightec signs Siemens commercial collaboration deal

InSightec's ultrasound system makes it possible to burn tissue in the body without damaging other tissue. Investor GE has waived exclusivity.

AACR 2016: Five-year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates

More than a third of metastatic melanoma patients (34 percent) who received the anti-PD-1 immunotherapeutic nivolumab (Opdivo) in a phase I clinical trial are still alive five years after starting treatment, according to research presented at the AACR...

CRISPR/Cas9, Familial Amyloid Polyneuropathy ( FAP) and Neurodegenerative Disease

CRISPR/Cas9, Familial Amyloid Polyneuropathy ( FAP) and Neurodegenerative Disease Curator: Larry H. Bernstein, MD, FCAP   CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-molecular-biology The development of efficient and reliable ways to make precise, targeted ...

#BIOWC16: “Cellulosic Biorefineries – Where Are We Today and Where will We Be Tomorrow”

“The Cellulosic Ethanol – Where are We Today and Where Will Be Tomorrow” panel started off the Advanced Biofuels and Biorefinery Platforms Track at the 2016 BIO World Congress on Industrial Biotechnology. Steve Hartig from ICM kicked off the panel by providing an overview of the current challenges in scaling up production of cellulosic ethanol. While large-scale cellulosic ethanol from cro...

A highly stretchable autonomous self-healing elastomer

Polymers that are both elastic and self-healing are desirable for a variety of applications, but often rely on hydrogen bonding which makes them moisture-sensitive. Now, by incorporating metal–ligand interactions with different bond strengths into flexible polymer backbones, an elastomer has been devised that combines high stretchability and high dielectric strength with autonomous self-healing ...

Counseling in Primary Care Clinics Helps Speed Recovery for Depressed Teens

PORTLAND, Ore., April 20, 2016 /PRNewswire/ -- Depressed teenagers who received cognitive behavioral therapy in their primary care clinic recovered faster, and were also more likely to recover, than teens who did not receive the primary care-based counseling, according to a Kaiser Permanente study published today in the journal Pediatrics. Primary care providers, such as pediatricians, are ...

In His New Book, "The Age Fix," Plastic Surgeon Reveals Sugar Is The Main Dietary Cause of Premature Aging

Doctor states, “Many surprising foods contain this skin damaging ingredient” Los Angeles, Calif. (PRWEB) April 20, 2016 In his new book, "The Age Fix: A Leading Plastic Surgeon Reveals How To Really Look Ten Years Younger," renowned board-certified plastic surgeon Dr. Anthony Youn reveals that the main dietary cause of premature aging is sugar: “Sugar equals wrinkles. No doubt abo...

Update from the AAN Conference: Clinical Insights on Multiple Sclerosis Management from AAN 2016

NeuroSeries Live and MS experts to webcast a live-online, cme accredited update and Q&A on developments in Multiple Sclerosis Management from the American Academy of Neurology's annual conference. Join neurology peers for this complimentary session on Tuesday, April 26th, 1PM EST at NeuroSeriesLive.com. Boston, Massachusetts (PRWEB) April 21, 2016 In the past decade, the MS treatment land...

Top 10 Big Pharma/Mid Pharma Immuno-Oncology Deals, 2011–15

The pace of immuno-oncology dealmaking has accelerated over the past two years. A look at the top 10 deals.

CRO Analytics and ACRP Unveil Site Voice™ Advisory Board Members

New Hope, PA, April 23, 2016 --(PR.com)-- CRO Analytics and the Association of Clinical Research Professionals (ACRP) announced the founding members of a diverse advisory board to build on groundbreaking research conducted by the two groups during the last year. Over the next several months, the Site Voice™ Advisory Board (SVAB) will oversee the collection of clinical research performance d...

Morphosys: Herber Rückschlag

von Julia Groß, Euro am Sonntag Bimagrumab, das Morphosys zusammen mit dem Schweizer Pharmariesen Novartis entwickelt hat, sollte eigentlich in diesem Jahr zur Zulassung eingereicht werden. Es wäre...

Veltassa filed for European approval

Swiss firm Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has submitted a Marketing Authorization…

Could gin distilled with collagen really be the fountain of youth?

The new gin — with the unfortunate name Anti-aGin — claims to rejuvenate the skin and help sippers defy age by dint of its collagen content.

PerkinElmer to Present at Bank of America Merrill Lynch 2016 Healthcare Conference

Wednesday, April 27th 2016 at 8:15pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Wednesday, May 11 at 2:20pm PT at the … Cet article PerkinElmer to Present ...

SCS Global Services Becomes Newest Non-GMO Project Verification Provider

Service Complements Broad Suite of Certifications for Food and Non-Food Products SOURCE: SCS Global Services DESCRIPTION:Emeryville, Calif., April 28, 2016 /3BL Media/ –  SCS Global Services (SCS) announced today that it has successfully completed a rigorous, year-long Non-GMO Project Verification Pilot Program, and is now formally recognized as Non-GMO Project Technical Administrator.  This...

Quick Search
Advertisement